Arcus Medical

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies by targeting key biological pathways involved in the tumor microenvironment. The company's portfolio is centered on the adenosine axis, the TIGIT/PVRIG pathway, and the HIF-2alpha axis, employing a combination of small molecules and monoclonal antibodies. Arcus has established a significant 10-year strategic collaboration with Gilead Sciences, which includes co-development and co-commercialization rights for several lead programs. Their most advanced candidates include domvanalimab, an anti-TIGIT antibody, and quemliclustat, a CD73 inhibitor, both of which are in late-stage clinical trials for various solid tumors. The company aims to create best-in-class combination therapies to improve outcomes for patients with high unmet medical needs in oncology.